A randomized, open-label, single-dose parallel study to evaluate the pharmacokinetics, safety and tolerability of HCP1803 in healthy male volunteers.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
20
Yangji Hospital
Seoul, South Korea
Cmax
pharmacokinetic evaluation
Time frame: 0~144hours
AUC last
pharmacokinetic evaluation
Time frame: 0~144hours
AUC inf
pharmacokinetic evaluation
Time frame: 0~144hours
Tmax
pharmacokinetic evaluation
Time frame: 0~144hours
t1/2
pharmacokinetic evaluation
Time frame: 0~144hours
CL/F
pharmacokinetic evaluation
Time frame: 0~144hours
Vd/F
pharmacokinetic evaluation
Time frame: 0~144hours
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.